Pictet Asset Management (Switzerland)’s Arcturus Therapeutics ARCT Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-70,374	Closed	-$1.11M	–	1569
2022 Q2	$1.11M	Buy	70,374 +20,532	+41%	+$403K	﹤0.01%	1032
2022 Q1	$1.34M	Sell	49,842 -11,088	-18%	-$283K	﹤0.01%	1021
2021 Q4	$2.25M	Hold	60,930	–	–	﹤0.01%	984
2021 Q3	$2.91M	Buy	+60,930	New	+$2.73M	﹤0.01%	937

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ARCT Position: Q3 2022 in Review

Pictet Asset Management (Switzerland) sold out of Arcturus Therapeutics (ARCT) in Q3 2022, closing a stake of 70,374 shares — an estimated $1.11M sold.

Pictet Asset Management (Switzerland) first reported a position in ARCT in Q3 2021 and held it in 4 quarters. The position peaked at $2.91M in Q3 2021. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

Pictet Asset Management (Switzerland) reported no remaining Arcturus Therapeutics position as of Q3 2022 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 70,374 Arcturus Therapeutics shares in Q3 2022, an estimated $1.11M.
Pictet Asset Management (Switzerland) first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 4 quarters.
Pictet Asset Management (Switzerland)'s Arcturus Therapeutics position peaked at $2.91M in Q3 2021.
116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q3 2022, filed 14 Nov 2022.